Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

Similar articles for PubMed (Select 21040901)


mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.

Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS, Gilliland DG, Morrison SJ.

Cell Stem Cell. 2010 Nov 5;7(5):593-605. doi: 10.1016/j.stem.2010.09.015.


Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression.

Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison SJ.

Cell Stem Cell. 2012 Sep 7;11(3):415-28. doi: 10.1016/j.stem.2012.05.026.


Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ.

Nature. 2006 May 25;441(7092):475-82. Epub 2006 Apr 5.


Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.

Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M.

Blood. 2011 Mar 31;117(13):3617-28. doi: 10.1182/blood-2009-12-261602. Epub 2011 Feb 2.


mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.

Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA.

Cell Stem Cell. 2012 Sep 7;11(3):429-39. doi: 10.1016/j.stem.2012.06.009.


PTEN in the haematopoietic system and its therapeutic indications.

Cheung AM, Mak TW.

Trends Mol Med. 2006 Nov;12(11):503-5. Epub 2006 Sep 25.


Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia.

Hirao A, Hoshii T.

Cancer Sci. 2013 Aug;104(8):977-82. doi: 10.1111/cas.12189. Epub 2013 Jun 9. Review.


IGF binding protein 2 supports the survival and cycling of hematopoietic stem cells.

Huynh H, Zheng J, Umikawa M, Zhang C, Silvany R, Iizuka S, Holzenberger M, Zhang W, Zhang CC.

Blood. 2011 Sep 22;118(12):3236-43. doi: 10.1182/blood-2011-01-331876. Epub 2011 Aug 5.


mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells.

Chen C, Liu Y, Liu Y, Zheng P.

Sci Signal. 2009 Nov 24;2(98):ra75. doi: 10.1126/scisignal.2000559.


Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells.

Nakada D, Saunders TL, Morrison SJ.

Nature. 2010 Dec 2;468(7324):653-8. doi: 10.1038/nature09571.


Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion.

Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S, Li L.

Genes Dev. 2011 Sep 15;25(18):1928-42. doi: 10.1101/gad.17421911. Epub 2011 Sep 2.


Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization.

Tesio M, Oser GM, Baccelli I, Blanco-Bose W, Wu H, Göthert JR, Kogan SC, Trumpp A.

J Exp Med. 2013 Oct 21;210(11):2337-49. doi: 10.1084/jem.20122768. Epub 2013 Oct 14.


Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice.

Oguro H, Iwama A, Morita Y, Kamijo T, van Lohuizen M, Nakauchi H.

J Exp Med. 2006 Oct 2;203(10):2247-53. Epub 2006 Sep 5.


PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway.

Cheng ZY, Guo XL, Yang XY, Niu ZY, Li SH, Wang SY, Chen H, Pan L.

J Exp Clin Cancer Res. 2008 Dec 30;27:87. doi: 10.1186/1756-9966-27-87.


Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K.

Blood. 2010 Feb 18;115(7):1406-15. doi: 10.1182/blood-2009-06-229443. Epub 2009 Dec 14.


PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.

Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG, Li S.

Blood. 2010 Jan 21;115(3):626-35. doi: 10.1182/blood-2009-06-228130. Epub 2009 Nov 18.


PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway.

Shi GD, OuYang YP, Shi JG, Liu Y, Yuan W, Jia LS.

Biochem Biophys Res Commun. 2011 Jan 28;404(4):941-5. doi: 10.1016/j.bbrc.2010.12.085. Epub 2010 Dec 23.


Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice.

Chen C, Liu Y, Liu Y, Zheng P.

J Clin Invest. 2010 Nov;120(11):4091-101. doi: 10.1172/JCI43873. Epub 2010 Oct 25. Erratum in: J Clin Invest. 2010 Dec 1;120(12):4583.


[Mechanism of hematopoietic stem/progenitor cell aging induced by radiation damage].

Zhang C, Sun K, Geng S, Liu D, Zhang X, Liu J, Xu C, Wang J, Wang Y.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Mar;29(3):233-6. Chinese.


Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma.

Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C.

Cancer Res. 2010 Nov 15;70(22):9143-52. doi: 10.1158/0008-5472.CAN-10-1758. Epub 2010 Nov 9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk